R&D Pipeline

R&D Pipeline(In-House)

As of February 2021

Development Stage

Development Code

(Generic name)
Development Classification

Expected indications Category

NDA

preparation

CCX168
(Avacopan)
In-licensed /
Vifor-Fresenius Medical Care Renal Pharma (Switzerland)

Microscopic polyangiitis
Granulomatosis with polyangiitis
- Selective complement C5a receptor antagonist -

Phase III

KPS-0373 *1
(Rovatirelin)
In-licensed /
Shionogi (Japan)

Spinocerebellar ataxia
- TRH receptor agonist -

AJM300 *2
(Carotegrast Methyl)
In-licensed /
Co-development with EA Pharma (Japan)

Ulcerative colitis
- Alpha 4 integrin receptor antagonist -

R788
(Fostamatinib)

In-licensed /
Rigel Pharmaceuticals (US)

Chronic idiopathic thrombocytopenic purpura
- Tyrosine kinase inhibitor -

MR13A9
(Difelikefalin)
In-licensed /
Co-development with Maruishi Pharmaceutical (Japan)

Uremic pruritus in dialysis patients
- Kappa opioid receptor agonist -

Phase II

KLH-2109
(Linzagolix)

Kissei

Endometriosis
- GnRH receptor antagonist -

KDT-3594 Kissei

Parkinson's disease
- Dopamine receptor agonist -


*1: Phase III clinical trial has been completed and we are currently consulting with PMDA
*2: Primary endpoint achieved



R&D Pipeline(Out-Licensing)

As of February 2021

Development Stage Generic name Development Company Countries & Regions Expected Indications
Category
NDA Mitiglinide Eisai(Japan) Vietnam Type 2 diabetes mellitus
Silodosin Eisai(Japan) Laos, Vietnam Dysuria associated with benign prostatic hyperplasia
Linzagolix
ObsEva SA (Switzerland) EU

Uterine fibroids
- GnRH receptor antagonist -

Phase III Linzagolix
ObsEva SA (Switzerland) US

Uterine fibroids
- GnRH receptor antagonist -

Linzagolix
ObsEva SA (Switzerland) EU, US

Endometriosis
- GnRH receptor antagonist -

Phase II Bedoradrine MediciNova(US) US

Acute exacerbation of asthma